摘要
阿伐那非是一种口服的高选择性磷酸二酯酶-5(PDE5)抑制剂,用于治疗勃起功能障碍(ED)。患者可在进行性行为之前30 min服用该药。它对PED5的作用效果大于其他已知的磷酸二酯酶,对阴茎勃起反应的影响与安慰剂相比显著改善。与其他的PDE5抑制剂一样,阿伐那非与部分降压药物合用是禁忌。阿伐那非无致癌、致突变和生殖毒性。
Avanafil is a orally and selective phosphodiesterase 5 （PDE5） inhibitor, which was approved by the Food and Drug Administration for the treatment of erectile dysfunction（ED）. Avanafil should be taken orally as needed approximately 30 minutes before sexual activity. It has superior selectivity for PDE5 when compared with other PDE isozymes,and improved erections after avanafil administration compared to placebo. Like other PDE5 inhibitors, avanafil administration with some antihypertensive drugs is contraindicated. Animal experiments show that avanafil has no carcinogenesis, mutagenesis and impairment of fertility.
出处
《广东化工》
CAS
2014年第17期109-110,共2页
Guangdong Chemical Industry
关键词
阿伐那非
药理
药效
毒理
avanafil： pharmacology： pharmacodynamics： toxicology
